Oncternal Therapeutics (NASDAQ:ONCT) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report issued on Wednesday morning. The firm issued a hold rating on the stock.

Oncternal Therapeutics Stock Performance

Shares of ONCT stock opened at $0.53 on Wednesday. The stock’s fifty day moving average is $0.53 and its 200-day moving average is $1.02. The stock has a market capitalization of $1.56 million, a PE ratio of -0.05 and a beta of 1.18. Oncternal Therapeutics has a 52 week low of $0.53 and a 52 week high of $9.88.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.